"Bear do you see where it explains why Vaccinex does not need xB3 to cross the BBB for treating patients with (i.e) Huntington's Disease assuming that is the case ?"

Let's break this down into two issues.

First, there are current antibody therapies that can cross the blood brain barrier to some degree and elicit some biological response without modification by xB3 or other similar technologies that enhance BBB crossing. The perfect case in point are the MANY anti-amyloid beta antibody therapies from various companies that have and still are being tested in clinical trials for Alzehimer's disease. Many of these anti-amyloid beta amyloid therapies have been shown to reduce amyloid plaque levels in the brain to varying degrees. Same logic probably holds true for non-amyloid antibody therapies from Vaccinex and others. They surely have some antibody therapies that can cross the BBB to some degree. But a marginal ability to cross the BBB means they need to administer a much higher dose to get enough into the brain.

Second, can technologies like xB3 enhance the ability of certain drugs (i.e. antibody therapies) to cross the BBB? YES! That is why we are, or should be, excited about Bioasis' xB3. They have shown that xB3 greatly enhances the ability of certain therapeutics (i.e. antibodies) to cross the BBB. This means: 1) a company can get more bang for their buck by having to administer less antibody to a patient to get the desired amount into the brain; and 2) some therapeutics that were shelved by a company because of little to no confidence of getting across the BBB in appreciable levels are now viable candidates again with the application of xB3.

All this noise just because Vaccinex decided to IPO? 

BearDownAZ